Forgot Password?
Return to Course Listing

CME: Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape

Activity Description / Statement of Need:

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a disease in which neoplastic clones of CD5+ cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. Men have close to twice the risk of women of developing CLL, and there are over 18,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400.

Target Audience:

HCPs including: medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with chronic lymphocytic leukemia.

Commercial Support Disclosure: This program is supported by an educational grant from BeiGene and Merck. 

This activity is free of charge.

Release Date: April 21, 2024 -- Expiration Date: April 21, 2025

Faculty: Matthew Davids, MD, MMSc


Introduction, disclosures  

Introductory content and review of chronic lymphocytic leukemia

  • Statistics and prognosis 
  • Disease burden 
  • Pre-treatment evaluation 

Updates in treatment in patients with R/R CLL 

  • Treatment goals 
  • A brief overview of choice of initial therapy, including monitoring principles and assessment of patient response 
  • Patient and disease-related factors driving therapeutic decision-making for R/R CLL, including: 
  • Prior therapies 
  • BTKi 
  • BCL-2i + anti-CD20 mAb 
  • Chemoimmunotherapy 
  • Treatment response 
  • Medical fitness 
  • Present pharmacotherapy, clinical trial findings, and guideline updates in R/R CLL 
  • BTKis 
  • BCL-2i 
  • PI3K inhibition 
  • Investigational agents, including those in the process of approval 
  • BTKis, including noncovalent 
  • CAR-T cell therapy 
  • Role of hematopoietic cell transplantation 
  • Challenges, including ongoing symptomology, adherence 
  • Patient case(s) 

Summary, conclusions, and best practice recap 

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the healthcare burden and barriers to effective identification and management of R/R CLL.
  • Describe present and emerging treatment options for R/R CLL, their present or anticipated place in therapy, and risk-benefit profiles.
  • Formulate a treatment plan for a patient with R/R CLL.


ACCME Activity #202780936

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-24-008-H01-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Matthew S. Davids, MD, MMSc, Associate Professor of Medicine, Harvard Medical School, has received financial compensation from Novartis, Ascentage Pharma and MEI Pharma for research support; AbbVie, Ascentage Pharma, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol-Meyers Squibb, Eli Lilly, Genentech, Genmab, Janssen, Merck, Nuvalent, SecuraBio, Takeda for consulting and honoraria from Aptitude Health and Axis Medical. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from BeiGene and Merck. 


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 and other recent society meetings

Transthyretin-mediated amyloidosis (ATTR): successful identification and its role in optimizing outcomes